Tag: Generalised Anxiety Disorder

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug ...

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...

As psychedelic medicine moves towards pharmaceutical development, Incannex is attempting to take synthetic psilocybin through the clinical, regulatory and commercial ...

Definium Therapeutics has reported positive Phase III results for its LSD-based medicine DT120 in generalised anxiety disorder, giving the company ...